Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

Abstract

Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action.

Keywords: BRCA mutation; PARP inhibitor; homologous recombination pathway; olaparib; ovarian cancer.